MDT-AP-1377
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 11.040000000000001
- os_event
- true
- age_years
- 3.08
- sex
- M
- new_clusters
- C2
- umap1_2d
- 2.360171894
- umap2_2d
- 0.404069075
- umap1_3d
- -0.648592958
- umap2_3d
- -2.027665098
- umap3_3d
- -1.01094375
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.730
- MYC_TARGETS_V1+0.590
- G2M_CHECKPOINT+0.550
- E2F_TARGETS+0.540
- MTORC1_SIGNALING+0.360
- DNA_REPAIR+0.350
- UNFOLDED_PROTEIN_RESPONSE+0.320
- MITOTIC_SPINDLE+0.210
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.190
- GLYCOLYSIS+0.150
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.480
- INTERFERON_GAMMA_RESPONSE-0.460
- KRAS_SIGNALING_UP-0.410
- COMPLEMENT-0.370
- IL6_JAK_STAT3_SIGNALING-0.370
- INFLAMMATORY_RESPONSE-0.360
- APICAL_SURFACE-0.340
- TNFA_SIGNALING_VIA_NFKB-0.320
- PROTEIN_SECRETION-0.310
- IL2_STAT5_SIGNALING-0.290
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 176e93be-1ae5-43f2-a0b5-17f31695e679 | — | — | 0.914 |
| 2 | MDT-AP-0134 | Med | Medulloblastoma | 0.913 |
| 3 | BS_9NZ2D6AD | Med | Medulloblastoma | 0.906 |
| 4 | TCGA-CQ-A4CI-01A-11R-A266-07 | — | — | 0.904 |
| 5 | ERR2208894 | — | — | 0.899 |
| 6 | fea46737-a2b3-49d4-8358-d0737546b6da | — | — | 0.896 |
| 7 | TCGA-XF-A9ST-01A-11R-A42T-07 | — | — | 0.891 |
| 8 | MDT-AP-2388 | Med | Medulloblastoma | 0.890 |
| 9 | SRR10900561 | — | — | 0.890 |
| 10 | TCGA-33-4532-01A-01R-1201-07 | — | cohortSQ2 | 0.889 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.730 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.590 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.550 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.540 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.360 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.350 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.320 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.210 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.190 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.150 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.130 | Inavolisib | — uncovered |
| PEROXISOME | 0.130 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.100 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.040 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.040 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.030 | Remibrutinib | — uncovered |
| UV_RESPONSE_UP | 0.020 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.010 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.010 | Inavolisib | — uncovered |